Research Department, Mediterranean Institute for Transplantation and Advanced Specialized Therapies (IRCCS ISMETT), Palermo, Italy.
Department of Laboratory Medicine and Advanced Biotechnologies, Mediterranean Institute for Transplantation and Advanced Specialized Therapies (IRCCS ISMETT), Palermo, Italy.
Front Immunol. 2022 Mar 24;13:856657. doi: 10.3389/fimmu.2022.856657. eCollection 2022.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes coronavirus disease 2019 (COVID-19), is modifying human activity all over the world with significant health and economic burden. The advent of the SARS-CoV-2 pandemic prompted the scientific community to learn the virus dynamics concerning transmissibility, epidemiology, and usefulness of vaccines in fighting emerging health hazards. Pieces of evidence suggest that the first and second doses of mRNA vaccines induce a significant antibody response in vaccinated subjects or patients who recovered from SARS-CoV-2 infection, demonstrating the importance of the previously formed memory. The aim of this work has been to investigate the effects of BNT162b2 Pfizer-BioNTech mRNA-based vaccine booster dose in a cohort of 11 uninfected immunocompetent (ICs), evaluating the humoral and cellular responses, with more carefulness on memory B and T cells. Our findings underscore the potential benefit of the third dose of mRNA vaccine on the lifespan of memory B and T cells, suggesting that booster doses could increase protection against SARS-CoV-2 infection.
严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）可引起 2019 年冠状病毒病（COVID-19），它正在全球范围内改变人类活动，给健康和经济带来巨大负担。SARS-CoV-2 大流行的出现促使科学界了解有关该病毒的传播力、流行病学和疫苗在应对新出现的健康危害方面的作用的动态。有证据表明，mRNA 疫苗的第一剂和第二剂在接种疫苗的受试者或从 SARS-CoV-2 感染中康复的患者中会引起显著的抗体反应，这表明先前形成的记忆的重要性。这项工作的目的是研究辉瑞-生物技术公司的基于 BNT162b2 的 mRNA 疫苗加强剂量在 11 名未感染的免疫功能正常（IC）人群中的作用，评估体液和细胞反应，并更加关注记忆 B 和 T 细胞。我们的研究结果强调了 mRNA 疫苗第三剂对记忆 B 和 T 细胞寿命的潜在益处，表明加强剂量可能会增加对 SARS-CoV-2 感染的保护。
